Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine and extrapyramidal side effects

D M Coulter1, P I Pillans

  • 1University of Otago Medical School, Dunedin, New Zealand.

The American Journal of Psychiatry
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.

Pharmacoepidemiology and drug safety·2008
Same author

Toenails and agranulocytosis.

Internal medicine journal·2007
Same author

Catastrophic intrauterine spinal cord injury caused by an arteriovenous malformation.

Journal of perinatology : official journal of the California Perinatal Association·2007
Same author

Heparin-induced thrombocytopenia: recent experience in a large teaching hospital.

Internal medicine journal·2006
Same author

Concordance between clopidogrel use and prescribing guidelines.

Internal medicine journal·2004
Same author

The New Zealand Intensive Medicines Monitoring Programme.

Pharmacoepidemiology and drug safety·2004

Fluoxetine may cause extrapyramidal side effects, including movement disorders. This risk may increase when fluoxetine is combined with other psychotropic medications or dopamine receptor blockers.

Area of Science:

  • Pharmacovigilance
  • Neuroscience
  • Clinical Pharmacology

Background:

  • Extrapyramidal side effects (EPS) are a known concern with certain psychotropic medications.
  • Understanding the potential for EPS with newer antidepressants like fluoxetine is crucial for patient safety.

Purpose of the Study:

  • To investigate the association between fluoxetine use and the occurrence of extrapyramidal side effects.
  • To determine if fluoxetine is causally related to reported extrapyramidal events.

Main Methods:

  • Analysis of adverse reaction reports from the New Zealand Intensive Medicines Monitoring Programme over a 4-year period.
  • Assessment of 5,555 patients receiving fluoxetine, focusing on notifications of extrapyramidal manifestations.

Main Results:

Related Experiment Videos

  • Fifteen cases of extrapyramidal events were reported as probably or possibly caused by fluoxetine.
  • In several cases, fluoxetine was the sole psychotropic agent; in others, it was co-administered with lithium, neuroleptics, tricyclic antidepressants, or metoclopramide.

Conclusions:

  • Fluoxetine may be associated with an increased risk of extrapyramidal reactions.
  • These reactions can occur with fluoxetine monotherapy or when fluoxetine is used concurrently with other psychotropic or dopamine receptor blocking drugs.